Black Diamond Therapeutics, Inc. (BDTX)

USD 1.78

(4.71%)

Market Cap (In USD)

100.88 Million

Revenue (In USD)

-

Net Income (In USD)

-82.44 Million

Avg. Volume

3.2 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.3-7.66
PE
-1.4
EPS
-1.27
Beta Value
2.518
ISIN
US09203E1055
CUSIP
09203E105
CIK
1701541
Shares
56676700.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Mark A. Velleca M.D., Ph.D.
Employee Count
-
Website
https://www.blackdiamondtherapeutics.com
Ipo Date
2020-01-31
Details
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.